Document:

Exhibit

Exhibit 10.1

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”

AMENDMENT NO. 2
TO SECOND AMENDED AND RESTATED NANTOMICS EXCLUSIVE RESELLER AGREEMENT

This Amendment No. 2 (the "Amendment") is made as of April 23, 2019 and shall be effective as of April 1, 2019 (the “Amendment Effective Date”), by and between NantHealth, Inc. (“NantHealth”) and NantOmics, LLC (“NantOmics”).

RECITALS

Whereas, NantHealth and NantOmics are parties to that certain Second Amended and Restated NantOmics Exclusive Reseller Agreement, effective as of June 19, 2015, as amended (the “Agreement”); 
 
Whereas, NantHealth and NantOmics wish to amend and clarify certain terms of the Agreement. 

Now, Therefore, the parties hereto, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound, agree as follows:

AGREEMENT

The Agreement is hereby amended as follows:

		
	1.
	With respect to Omics Services completed by NantOmics and billed by NantHealth between the Amendment Effective Date and the end of the Initial Term, NantHealth shall pay NantOmics a fixed fee of [***] (instead of the fee otherwise provided/calculated under Section 3.1 of the Agreement).

		
	2.
	Except as set forth in this Amendment, the Agreement is unaffected and shall continue in full force and effect in accordance with its terms. Except as otherwise modified or defined herein, all capitalized terms in this Amendment have the same meanings as set forth in the Agreement.  If there is conflict between this amendment and the Agreement or any earlier amendment, the terms of this Amendment will prevail.

IN WITNESS HEREOF, the parties have agreed and fully executed this Amendment.

	
				
	NantHealth, Inc.
	 
	 
	NantOmics, LLC

	 
	 
	 
	 

	By: /s/ Bob Petrou                    
	 
	 
	By: /s/ Charles Kim      

	 
	 
	 
	 

	Name: Bob Petrou    
	 
	 
	Name:  Charles Kim

	 
	 
	 
	 

	Title: Interim Chief Financial Officer
	 
	 
	Title: General Counsel

	 
	 
	 
	 

	 
	 
	 
	 

	 
	 
	 
	 

[***]Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.Exhibit 10.1

 

SETTLEMENT
AGREEMENT

 

This
SETTLEMENT AGREEMENT (this “Agreement”) is made and entered into as of May 9, 2019, by and among Knowles
Corporation, a Delaware corporation (the “Company”), on the one hand, and Caligan Partners CV I LP, a Cayman
Islands exempted limited partnership (“Caligan CV I”), Caligan Partners LP, a Delaware limited partnership,
Caligan Partners CV GP LLC, a Delaware limited liability company, Caligan Partners GP, LLC, a Delaware limited liability company,
Falcon Edge Capital, LP, a Delaware limited partnership, Falcon Edge (Cayman) GP, Ltd., a Cayman Islands Corporation, Falcon Edge
Global Master Fund, LP, a Cayman Islands exempted limited partnership, Moraine Master Fund, LP, a Cayman Islands exempted limited
partnership, Patriot Global Management, LP, a Delaware limited partnership, Samuel J. Merksamer, an individual, David E. Johnson,
an individual, and Jonathan Christodoro, an individual (the foregoing, together with Caligan CV I, and collectively with each
of their respective Affiliates, the “Investor Group”), on the other hand. The Company and the Investor Group
are each herein referred to as a “party” and collectively, the “parties.”

 

WHEREAS,
on March 11, 2019, certain members of the Investor Group filed a Schedule 13D (the “Schedule 13D”) with the
SEC;

 

WHEREAS,
on January 30, 2019, Caligan CV I submitted notice (the “Initial Nomination Notice") of its intent to nominate
three candidates for election to the Board of Directors of the Company (the “Board”) at the Company’s
2019 Annual Meeting of Stockholders (the “2019 Annual Meeting”);

 

WHEREAS,
on March 11, 2019, Caligan CV I submitted a supplement to the Initial Nomination Notice (together with the Initial Nomination
Notice, the “Nomination Notice”) whereby Caligan CV I, among other things, withdrew one of its three director
candidates; and

 

WHEREAS,
the Company and the Investor Group have determined to come to an agreement with respect to the composition of the Board and certain
other matters, as provided in this Agreement;

 

NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally
bound hereby, agree as follows:

 

1.
 Board Composition and Related Matters.

 

(a) Effective
upon the execution and delivery of this Agreement, Caligan CV I has withdrawn the Nomination Notice by submitting the form attached
hereto as Exhibit A to the Company.

 

(b) Effective
upon the execution and delivery of this Agreement, the Board increases the size of the Board from nine to ten directors with a
resulting vacancy in Class III of the Board.

 

     

     

    

 

(c) Simultaneous
with the execution and delivery of this Agreement and as a condition to the Investor Group’s rights and the Board’s
obligations herein, Steven F. Mayer (the “Investor Group Designee”), has executed and delivered to the Company
a designee agreement in the form attached hereto as Exhibit B (the “Designee Agreement”).

 

(d) The
Company shall, as promptly as practicable following the execution of this Agreement, but in no case later than two Business Days
following the date of this Agreement, take all action necessary to appoint the Investor Group Designee to the Board to fill the
vacancy resulting from the increase in the size of the Board as set forth in Section 1(b).

 

(e) The
Company shall, with respect to the 2019 Annual Meeting, 2020 Annual Meeting and, subject to the Company’s delivery of a
Renomination Notice pursuant to Section 11(a) that has not been declined by the Investor Group or the Investor Group Designee,
any subsequent Annual Meetings during the term of this Agreement, (i) include the Investor Group Designee as a nominee for election
to the Board in its proxy statement and proxy card, (ii) recommend to the stockholders of the Company the election of the Investor
Group Designee to the Board and (iii) solicit proxies in favor of the election of the Investor Group Designee to the Board in
a manner no less rigorous and favorable than the manner in which the Company supports its other incumbent nominees.

 

(f) Concurrently
with the Investor Group Designee’s appointment to the Board, the Board shall take the necessary steps to appoint and seat
the Investor Group Designee on at least one committee of the Board, subject to applicable rules of the SEC and of any stock exchange
on which the Company is traded and as selected by the Board in its sole discretion. The Investor Group Designee shall be entitled
to continuously serve on such committee until the Termination Date.

 

(g) The
Investor Group agrees that the Board or any committee thereof, in the exercise of its fiduciary duties, may recuse the Investor
Group Designee from any portion of a Board or committee meeting, and restrict access to information of the Company, to the extent
relating to (i) this Agreement, including the interpretation and enforcement thereof, (ii) any demand made by any member of the
Investor Group or any of their respective Affiliates if such demand is coupled, expressly or implied, with the threat to take
any of the actions prohibited in Sections 3(a) through 3(l), (iii) the Designee Agreement, (iv) the Investor Group
Designee’s failure to comply with the Company’s Amended and Restated Certificate of Incorporation (as amended and
as may be further amended from time to time, the “Charter”), the Company’s Amended and Restated By-Laws
(as amended and as may be further amended from time to time, the “By-Laws”) or policies that are applicable
to all directors or (v) any proposed transaction between the Company and any member of the Investor Group or any of their respective
Affiliates. For the avoidance of doubt, the Investor Group acknowledges and agrees that: (A) pursuant to the Designee Agreement
and consistent with his fiduciary duties as a director of the Company, the Investor Group Designee is obligated to consider in
good faith, to the same extent as any other director of the Company, recusal from any Board or committee meeting in the event
there is any other actual or potential conflict of interest between the Investor Group or the Investor Group Designee, on the
one hand, and the Company, on the other hand; and (B) the Board may restrict the Investor Group Designee’s access to information
of the Company to the same extent it would for any other director of the Company, in accordance with applicable law.

 

    2

     

    

 

(h)
The Investor Group agrees that there shall be no contracts, plans or arrangements, written or otherwise, in effect during the
term of this Agreement, between any members of the Investor Group and the Investor Group Designee providing for any
compensation, reimbursement of expenses or indemnification of the Investor Group Designee in connection with or related to
the Investor Group Designee’s service on the Board, other than the reimbursement agreement (the “Reimbursement
Agreement”) in the form attached hereto as Exhibit C.

 

(i) The
Investor Group acknowledges and agrees that if at any time during the term of this Agreement the Investor Group and its Affiliates’
aggregate Net Long Position falls below 4,549,989 shares of common stock of the Company, par value $0.01 per share (the “Common
Stock”) (subject to adjustment for stock splits, reclassifications and combinations, the “Ownership Minimum”),
(i) the rights of the members of the Investor Group and the obligations of the Company pursuant to this Section 1
shall terminate immediately and (ii) the Investor Group Designee is obligated to immediately tender his resignation pursuant to
the Designee Agreement (it being understood that the Board shall have the right to decline to accept such resignation).

 

(j) Until
the Termination Date and as long as the Investor Group and its Affiliates’ Net Long Position exceeds the Ownership Minimum,
in the event that the Investor Group Designee is no longer able to serve as a director of the Company due to death, disability
or other incapacity, the members of the Investor Group shall be entitled to designate, subject to the approval of the Governance
and Nominating Committee of the Board (the “Governance and Nominating Committee”), a candidate for replacement
of the Investor Group Designee (such replacement, a “Replacement Designee”). Any Replacement Designee shall
qualify as an “independent director” under applicable rules of the SEC, the rules of any stock exchange on which the
Company is traded and applicable governance policies of the Company. The Governance and Nominating Committee shall, in good faith
and consistent with its fiduciary duties, approve or deny any candidate for Replacement Designee within ten Business Days after
such candidate has: (i) successfully completed a customary background check; (ii) completed a satisfactory interview with the
Governance and Nominating Committee; (iii) provided the Company with (A) a completed director questionnaire (in the form to be
provided by the Company), (B) an executed Designee Agreement and (C) such other information required by the documents described
in the Designee Agreement or as may be reasonably requested by the Company and (iv) agreed to take all necessary action not be
considered to be “overboarded” under the applicable policies of Institutional Shareholder Services, Inc. (“ISS”)
and/or Glass Lewis & Co., LLC (“Glass Lewis”) as a result of his or her appointment to the Board. In the
event the Governance and Nominating Committee declines to approve a candidate for Replacement Designee, (i) any agreements provided
by such candidate pursuant to the previous sentence shall be null and void and of no effect and (ii) the members of the Investor
Group may propose one or more additional candidates, subject to the approval process described above, until a Replacement Designee
is approved by the Governance and Nominating Committee. Following the approval of a candidate for Replacement Designee by the
Governance and Nominating Committee, the Board shall promptly appoint such Replacement Designee to the Board. Upon his or her
appointment to the Board, such Replacement Designee shall be deemed to be an Investor Group Designee for all purposes under this
Agreement.

 

    3

     

    

 

(k) No
later than the date that is 120 calendar days after the Company’s 2020 Annual Meeting, the Board and the members of the
Investor Group shall cooperate to identify a mutually acceptable Independent Director (the “New Independent Director”)
for appointment to the Board. If the Company and the members of the Investor Group, after good faith efforts, are not able to
identify a mutually acceptable candidate to serve as the New Independent Director by such date, then the Board, in its sole discretion,
shall take all actions reasonably necessary to select a New Independent Director in accordance with the Board’s internal
procedures and consistent with all applicable corporate governance policies of the Company; provided, that appointment
of the New Independent Director shall be subject to the approval of the members of the Investor Group (not to be unreasonably
withheld, conditioned or delayed). Following the selection of the New Independent Director and the approval of the members of
the Investor Group, the Board shall promptly appoint the New Independent Director to the Board.

 

2. Voting
Commitment. Until the Termination Date, the members of the Investor Group shall, or shall cause their Representatives
to, appear in person or by proxy at each Stockholder Meeting and to vote all shares of Common Stock beneficially owned by it and
over which it has voting power in accordance with the Board’s recommendations as such recommendations of the Board are set
forth in the applicable definitive proxy statement filed in respect thereof with respect to (a) the election, removal and/or replacement
of directors (a “Director Proposal”) and (b) any other proposal submitted to the stockholders at a Stockholder
Meeting other than a proposal with respect to an Extraordinary Transaction, in each case as such recommendation of the Board is
set forth in the applicable definitive proxy statement filed in respect thereof; provided, however, that in the event both
ISS and Glass Lewis make voting recommendations that differ from the voting recommendation of the Board with respect to any Company
proposal (other than Director Proposals) submitted to the stockholders at any Stockholder Meeting, the members of the Investor
Group shall be permitted to vote all or some shares of Common Stock they beneficially own and over which they have voting power
at such Stockholder Meeting in accordance with the ISS and Glass Lewis recommendations.

 

3. Standstill.
Prior to the Termination Date, except as otherwise provided in this Agreement (including Section 11(a)), without the prior
written consent of the Board, the members of the Investor Group shall not, and shall instruct their Affiliates, not to, directly
or indirectly (in each case, except as permitted by this Agreement):

 

(a) (i)
acquire, offer or seek to acquire, agree to acquire or acquire rights to acquire (except by way of stock dividends or other distributions
or offerings made available to holders of voting securities of the Company generally on a pro rata basis), directly or indirectly,
whether by purchase, tender or exchange offer, through the acquisition of control of another person, by joining a group, through
swap or hedging transactions or otherwise, any voting securities of the Company (other than through a broad-based market basket
or index) or any voting rights decoupled from the underlying voting securities which would result in the ownership or control
of, or other beneficial ownership interest in, 10.0% or more than of the then-outstanding shares of the Common Stock in the aggregate
(the “Ownership Cap”); provided, however, that the Board may increase the Ownership Cap by an
affirmative vote of a majority of the Board; or (ii) sell its shares of Common Stock, other than in open market sale transactions
where the identity of the purchaser is not known and in underwritten widely dispersed public offerings, to any Third Party that,
to the Investor Group’s knowledge (after due inquiry in connection with a private, non-open market transaction, it being
understood that such knowledge shall be deemed to exist with respect to any publicly available information, including information
in documents filed with the SEC), would result in such Third Party, together with its Affiliates and Associates, owning, controlling
or otherwise having any beneficial or other ownership interest in the aggregate of more than 4.9% of the shares of Common Stock
outstanding at such time or would increase the beneficial ownership interest of any Third Party who, together with its Affiliates
and Associates, has a beneficial or other ownership interest in the aggregate of more than 4.9% of the shares of Common Stock
outstanding at such time;

 

    4

     

    

 

(b) (i)
other than pursuant to Section 1(j) of this Agreement, nominate, recommend for nomination or give notice of an intent to
nominate or recommend for nomination a person for election at any Stockholder Meeting at which the Company’s directors are
to be elected; (ii) knowingly initiate, encourage or participate in any solicitation of proxies in respect of any election contest
or removal contest with respect to the Company’s directors; (iii) submit, initiate, make or be a proponent of any stockholder
proposal for consideration at, or bring any other business before, any Stockholder Meeting; (iv) knowingly initiate, encourage
or participate in any solicitation of proxies in respect of any stockholder proposal for consideration at, or other business brought
before, any Stockholder Meeting; or (v) knowingly initiate, encourage or participate in any “withhold” or similar
campaign with respect to any Stockholder Meeting;

 

(c) form,
join or in any way participate in any group or agreement of any kind with respect to any voting securities of the Company, including
in connection with any election or removal contest with respect to the Company’s directors or any stockholder proposal or
other business brought before any Stockholder Meeting (other than with the members of the Investor Group or one or more of their
Affiliates and Associates who are instructed to comply by the terms and conditions of this Agreement);

 

(d) deposit
any voting securities of the Company in any voting trust or subject any Company voting securities to any arrangement or agreement
with respect to the voting thereof (other than any such voting trust, arrangement or agreement solely among members of the Investor
Group and otherwise in accordance with this Agreement);

 

(e) seek
publicly, alone or in concert with others, to amend any provision of the Charter or By-Laws;

 

(f) demand
an inspection of the Company’s books and records;

 

(g) (i)
make any public or private proposal with respect to or (ii) make any public statement or otherwise seek to encourage, advise or
assist any person in so encouraging or advising with respect to: (A) any change in the number or term of directors serving on
the Board or the filling of any vacancies on the Board, (B) any change in the capitalization or dividend policy of the Company,
(C) any other change in the Company’s management, governance, corporate structure, affairs or policies, (D) any Extraordinary
Transaction, (E) causing a class of securities of the Company to be delisted from, or to cease to be authorized to be quoted on,
any securities exchange or (F) causing a class of equity securities of the Company to become eligible for termination of registration
pursuant to Section 12(g)(4) of the Exchange Act;

 

    5

     

    

 

(h) knowingly
initiate, make or in any way participate, directly or indirectly, in any Extraordinary Transaction or make, directly or indirectly,
any proposal, either alone or in concert with others, to the Company or the Board that would reasonably be expected to require
a public announcement or disclosure regarding any such matter;

 

(i) effect
or seek to effect, offer or propose to effect, cause or participate in, or in any way knowingly assist or facilitate any other
person to effect or seek, offer or propose to effect or participate in, any (i) material acquisition of any assets or businesses
of the Company or any of its subsidiaries; (ii) tender offer or exchange offer, merger, acquisition, share exchange or other business
combination involving any of the voting securities or any of the material assets or businesses of the Company or any of its subsidiaries;
or (iii) recapitalization, restructuring, liquidation, dissolution or other material transaction with respect to the Company or
any of its subsidiaries or any material portion of its or their businesses;

 

(j) enter
into any negotiations, agreements or understandings with any Third Party with respect to the foregoing, or advise, assist, encourage
or seek to persuade any Third Party to take any action with respect to any of the foregoing, or otherwise take or cause any action
inconsistent with any of the foregoing;

 

(k) publicly
make or in any way advance publicly any request or proposal that the Company or the Board amend, modify or waive any provision
of this Agreement; or

 

(l) take
any action challenging the validity or enforceability of this Section 3 or this Agreement unless the Company is challenging
the validity or enforceability of this Agreement.

 

provided,
however, that (i) the restrictions in this Section 3 shall not prevent the members of the Investor Group from making
(a) any factual statement as required by applicable legal process, subpoena or legal requirement from any governmental authority
with competent jurisdiction over the party from whom information is sought (so long as such request did not arise as a result
of action by any of the members of the Investor Group) or (b) any confidential communication to the Company that would not be
reasonably expected to trigger public disclosure obligations for either party and (ii) the restrictions in this Section 3
shall not restrict the members of the Investor Group from tendering shares, receiving payment for shares or otherwise participating
in any such transaction on the same basis as the other stockholders of the Company or from participating in any such transaction
that has been approved by the Board, subject to the other terms of this Agreement. For the avoidance of doubt, nothing in this
Section 3 shall be deemed to limit the exercise in good faith by the Investor Group Designee of his fiduciary duties in his capacity
as a director of the Company.

 

4. Mutual
Non-Disparagement. Prior to the Termination Date, without the prior written consent of the other party, neither party
shall, nor shall it permit any of its Representatives to make any public statement about the other party, the other party’s
current or former directors in their capacity as such, officers or employees (including with respect to such persons’ service
at the other party), the other party’s subsidiaries, or the business of the other party’s subsidiaries or any of its
or its subsidiaries’ current directors, officers or employees, including the business and current or former directors, officers
and employees of the other party’s controlled Affiliates, as applicable. The restrictions in this Section 4
shall not (x) apply (i) in any compelled testimony or production of information, whether by legal process, subpoena or as part
of a response to a request for information from any governmental or regulatory authority with jurisdiction over the party from
whom information is sought, in each case, to the extent required, or (ii) to any disclosure that such party reasonably believes,
after consultation with outside counsel, to be legally required by applicable law, rules or regulations; or (y) prohibit any party
from reporting what it reasonably believes, after consultation with outside counsel, to be violations of federal law or regulation
to any governmental authority pursuant to Section 21F of the Exchange Act or Rule 21F promulgated thereunder.

 

    6

     

    

 

5. No
Litigation. Prior to the Termination Date, each party hereby covenants and agrees that it shall not, and shall not permit
any of its Representatives to, directly or indirectly, alone or in concert with others, encourage, pursue or assist any other
person to threaten or initiate, any lawsuit, claim or proceeding before any court (each, a “Legal Proceeding”)
against the other party or any of its Representatives, except for (a) any Legal Proceeding initiated primarily to remedy a breach
of or to enforce this Agreement and (b) counterclaims with respect to any proceeding initiated by, or on behalf of one party or
its Affiliates against the other party or its Affiliates; provided, however, that the foregoing shall not prevent
any party or any of its Representatives from responding to oral questions, interrogatories, requests for information or documents,
subpoenas, civil investigative demands or similar processes (each, a “Legal Requirement”) in connection with
any Legal Proceeding if such Legal Proceeding has not been initiated by, on behalf of or at the direct or indirect suggestion
of such party or any of its Representatives; provided, further, that in the event any party or any of its Representatives
receives such Legal Requirement, such party shall give prompt written notice of such Legal Requirement to the other party (except
where such notice would be legally prohibited or not practicable). Each party represents and warrants that neither it nor any
assignee has filed any lawsuit against the other party.

 

6. Public
Statements; SEC Filings.

 

(a) No
later than two Business Days following the date of this Agreement, the Company shall issue a press release (the “Press
Release”) announcing this Agreement, substantially in the form attached hereto as Exhibit D. Prior to the issuance
of the Press Release, neither the Company nor the members of the Investor Group shall issue any press release or public announcement
regarding this Agreement or take any action that would require public disclosure thereof without the prior written consent of
the other party.

 

(b) No
later than two Business Days following the date of this Agreement, the Company shall file with the SEC a Current Report on Form
8-K reporting its entry into this Agreement, disclosing applicable items to conform to its obligations hereunder and appending
this Agreement as an exhibit thereto (the “Form 8-K”). The Form 8-K shall be consistent with the terms of this
Agreement and the Press Release. The Company shall provide the members of the Investor Group and their Representatives with a
reasonable opportunity to review and comment on the Form 8-K prior to the filing with the SEC and consider in good faith any comments
of the members of the Investor Group and their Representatives.

 

(c) No
later than two Business Days following the date of this Agreement, the Investor Group shall file with the SEC an amendment to
its Schedule 13D in compliance with Section 13 of the Exchange Act reporting its entry into this Agreement, disclosing applicable
items to conform to its obligations hereunder and including the terms of this Agreement and the Reimbursement Agreement and including
this Agreement as an exhibit thereto (the “Schedule 13D Amendment”). The Schedule 13D Amendment shall
be consistent with the terms of this Agreement and the Press Release. The Investor Group shall provide the Company and its Representatives
with a reasonable opportunity to review the Schedule 13D Amendment prior to it being filed with the SEC and consider in good faith
any comments of the Company and its Representatives.

 

    7

     

    

 

(d) Except
for the issuance of the Press Release and the filing of the Form 8-K and Schedule 13D Amendment, no party shall issue any press
release or other public statement (including, without limitation, in any filing required under the Exchange Act) or speak with
any member of the media about the subject matter of this Agreement or the other party, except as required by law, Legal Requirement
or applicable stock exchange listing rules or with the prior written consent of the other party and otherwise in accordance with
this Agreement.

 

 7.  Confidentiality.

 

(a) For
so long as the Investor Group Designee is serving as a director on the Board, the Investor Group and its Representatives may receive
confidential information of the Company from the Investor Group Designee which he learns in his capacity as a director of the
Company, including discussions or matters considered in meetings of the Board or Board committees (collectively and individually,
“Confidential Information”); provided, however, that the Investor Group and the Investor Group Designee
shall have executed a confidentiality agreement with the Company in the form attached hereto as Exhibit E (a “Confidentiality
Agreement”) prior to the receipt of Confidential Information by the members of the Investor Group or their Representatives
from the Investor Group Designee; provided, further, that in the event that a Replacement Designee is appointed to the
Board pursuant to Section 1(j), the Investor Group and its Representatives may not receive Confidential Information from
such Replacement Designee unless and until the Company, the Investor Group and such Replacement Designee shall have executed an
amendment or joinder to the Confidentiality Agreement to join such Replacement Designee to the Confidentiality Agreement as the
Investor Group Director thereunder.

 

(b) For
the avoidance of doubt, the parties acknowledge and agree that the obligations of the Investor Group under this Section 
7 and of the Investor Group Designee under the Designee Agreement shall be in addition to, and not in lieu of, the Investor
Group Designee’s confidentiality obligations under Delaware law and the Charter, By-Laws and applicable corporate governance
policies of the Company; provided, that in the event of a conflict between the Investor Group Designee’s confidentiality
obligations under the applicable corporate governance policies of the Company and those in the Confidentiality Agreement, the
terms of the Confidentiality Agreement shall control.

 

8. Compliance
with Securities Laws. The Investor Group acknowledges that it understands its obligations under the U.S. securities laws.
Subject to compliance with such laws, the members of the Investor Group and their Representatives shall in any event be free to
trade or engage in such transactions during periods when the members of the Board are permitted to do so, and the Company will
notify the members of the Investor Group reasonably in advance when such “open window” director trading periods begin
and end. The Company acknowledges that none of the provisions herein shall in any way limit the activities of the members of the
Investor Group or their Representatives in their respective ordinary course of businesses if such activities will not violate
applicable securities laws or the obligations specifically agreed to under this Agreement. In addition, nothing contained in this
Agreement shall restrict the ability of the members of the Investor Group or their Representatives from purchasing, selling or
otherwise trading securities of the Company pursuant to any Rule 10b5-1 trading plan adopted prior to the execution of this Agreement.

 

    8

     

    

 

9. Affiliates
and Associates. Each party shall instruct its controlled Affiliates and Associates to comply with the terms of this Agreement
and shall be responsible for any breach of this Agreement by any such controlled Affiliate or Associate. A breach of this Agreement
by a controlled Affiliate or Associate of a party, if such controlled Affiliate or Associate is not a party to this Agreement,
shall be deemed to occur if such controlled Affiliate or Associate engages in conduct that would constitute a breach of this Agreement
if such controlled Affiliate or Associate was a party to the same extent as a party to this Agreement.

 

 10.  Representations and Warranties.

 

(a) The
Investor Group represents and warrants that it has full power and authority to execute, deliver and carry out the terms and provisions
of this Agreement and to consummate the transactions contemplated hereby, and that this Agreement has been duly and validly executed
and delivered by it, constitutes a valid and binding obligation and agreement of it and is enforceable against it in accordance
with its terms. The Investor Group represents that the execution of this Agreement, the consummation of any of the transactions
contemplated hereby, and the fulfillment of the terms hereof, in each case in accordance with the terms hereof, will not conflict
with, or result in a breach or violation of the organizational documents of it as currently in effect, the execution, delivery
and performance of this Agreement by it does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment
or decree applicable to it or (ii) result in any breach or violation of or constitute a default (or an event which with notice
or lapse of time or both could constitute such a breach, violation or default) under or pursuant to, or result in the loss of
a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document,
agreement, contract, commitment, understanding or arrangement to which it is a party or by which it is bound. The Investor Group
represents and warrants that, as of the date of this Agreement, it beneficially owns an aggregate of 6,651,906 shares of Common
Stock. The Investor Group represents and warrants that it has voting authority over such shares and owns no Synthetic Equity Interests
or any Short Interests in the Company.

 

(b) The
Company hereby represents and warrants that it has the power and authority to execute, deliver and carry out the terms and provisions
of this Agreement and to consummate the transactions contemplated hereby, and that this Agreement has been duly and validly authorized,
executed and delivered by the Company, constitutes a valid and binding obligation and agreement of the Company and is enforceable
against the Company in accordance with its terms. The Company represents that the execution of this Agreement, the consummation
of any of the transactions contemplated hereby, and the fulfillment of the terms hereof, in each case in accordance with the terms
hereof, will not conflict with, or result in a breach or violation of the organizational documents of the Company as currently
in effect, the execution, delivery and performance of this Agreement by the Company does not and will not violate or conflict
with (i) any law, rule, regulation, order, judgment or decree applicable to the Company or (ii) result in any breach or violation
of or constitute a default (or an event which with notice or lapse of time or both could constitute such a breach, violation or
default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment,
acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to
which the Company is a party or by which it is bound.

 

    9

     

    

 

11. Termination.

 

(a) Either
party shall have the right to terminate this Agreement upon delivery to the other party of advance written notice of such termination
at least five Business Days prior to the date of such termination (the effective date of termination, the “Termination
Date”); provided, however, that neither party shall be permitted to terminate this Agreement until the date that
is 30 calendar days prior to the notice deadline under the By-Laws for the nomination of director candidates for election to the
Board at the 2021 Annual Meeting; provided, further, that the Company shall deliver irrevocable written notice to the Investor
Group if it intends to include the Investor Group Designee in its slate of candidates for election to the Board and to comply
with its obligations under Section 1(e) with respect to the 2021 Annual Meeting and any subsequent Annual Meeting at least
45 calendar days prior to the notice deadline under the By-Laws for the nomination of director candidates for election to the
Board at such Annual Meeting, and, if the Investor Group or the Investor Group Designee does not decline such renomination in
writing by the date that is 30 calendar days prior to the notice deadline under the By-Laws for the nomination of director candidates
for election to the Board at such Annual Meeting, then the Investor Group shall not be permitted to terminate this Agreement pursuant
to this Section 11(a) until after the date of such Annual Meeting (for the avoidance of doubt, nothing in this Section
11(a) shall require the Company to nominate the Investor Group Designee for election to the Board at any Annual Meeting occurring
after the Termination Date); provided, further, that no party shall be permitted to terminate this Agreement in any time
period between the notice deadline under the By-Laws for the nomination of director candidates for election to the Board with
respect to any Annual Meeting and the conclusion of such Annual Meeting. Notwithstanding anything to the contrary in this Agreement:

 

(i) the
obligations of the Investor Group pursuant to Sections 1, 2, 3, 4, 5 and 6(d) shall terminate
in the event that the Company materially breaches its obligations to the Investor Group pursuant to Sections 1, 4
or 5, or the representations and warranties in Section 10(b) of this Agreement and such breach (if capable
of being cured) has not been cured within ten calendar days following written notice of such breach from the Investor Group, or,
if impossible to cure within ten calendar days, the Company has not taken substantive action to correct within ten calendar days
following written notice of such breach from the Investor Group; provided, however, that the obligations of the
Investor Group pursuant to Section 5 shall terminate immediately in the event that the Company materially breaches
its obligations to the Investor Group under Section 5; and

 

    10

     

    

 

(ii) the
obligations of the Company to the Investor Group pursuant to Sections 1, 4 and 5 shall terminate in
the event that (A) the Investor Group materially breaches its obligations in Sections 1, 2, 3, 4,
5, 6(d), 7 or 8 or the representations and warranties in Section 10(a), or (B) the Investor Group
Designee materially breaches the Designee Agreement, and such breach (if capable of being cured) has not been cured within ten
calendar days following written notice of such breach, or, if impossible to cure within ten calendar days, the Investor Group
Designee has not taken substantive action to correct within ten calendar days following written notice of such breach from the
Company; provided, however, that the obligations of the Company to the Investor Group pursuant to Section 5
shall terminate immediately in the event that the Investor Group materially breaches its obligations under Section 5.

 

(b) If
this Agreement is terminated in accordance with this Section 11, this Agreement shall forthwith become null and void,
but no termination shall relieve either party from liability for any breach of this Agreement prior to such termination.

 

12. Expenses.
The Company shall reimburse the Investor Group for its reasonable, documented out-of-pocket fees and expenses (including legal
expenses) incurred in connection with the subject matter of this Agreement, provided that such reimbursement shall not exceed
$750,000 in the aggregate.

 

13. Notices.
 All notices, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement
shall be in writing and shall be deemed to have been given (a) when delivered by hand, with written confirmation of receipt; (b)
upon sending if sent by electronic mail to the electronic mail addresses below, with confirmation of receipt from the receiving
party by electronic mail; (c) one Business Day after being sent by a nationally recognized overnight carrier to the addresses
set forth below; or (d) when actually delivered if sent by any other method that results in delivery, with written confirmation
of receipt:

 

	If
                                         to the Company:

        
	with
                                         mandatory copies (which shall not constitute notice) to:

        

	 	 
	Knowles
    Corporation
        1151
        Maplewood Drive

        Itasca,
        Illinois 60143

        Attn:
        Thomas Jackson, General Counsel

        Email:
        thomas.jackson@knowles.com
	Sidley
    Austin LLP
        787
        Seventh Avenue

        New
        York, NY 10019

        Attn:
        Kai H. Liekefett

                  Paul
        L. Choi

        Email:
        kliekefett@sidley.com

                   pchoi@sidley.com

	 	 
	

        If
        to the Investor Group:

        
	

        with
        mandatory copies (which shall not constitute notice) to:

	 	 
	Caligan

                                                         520
                                         Madison Avenue

                                                         New
                                         York, NY 10022

        Attn:
        David E. Johnson

        Email:
        dj@caliganpartners.com

        
	

        Schulte
        Roth & Zabel LLP

        919
        Third Avenue

        New
        York, NY 10022

        Attn:
        Eleazer Klein

        Email:
        eleazer.klein@srz.com

	 	 
	Falcon
                                         Edge

                                                         660
                                         Madison Avenue, 19th Floor

                                                         New
                                         York, NY 10065

        Attn:
        Mark Cho

        Email:
        mcho@falconedge.com

        
	

         

 

    11

     

    

 

14. Governing
Law; Jurisdiction; Jury Waiver. This Agreement, and any disputes arising out of or related to this Agreement (whether
for breach of contract, tortious conduct or otherwise), shall be governed by, and construed in accordance with, the laws of the
State of Delaware, without giving effect to its conflict of laws principles. The parties agree that exclusive jurisdiction and
venue for any Legal Proceeding arising out of or related to this Agreement shall exclusively lie in the Court of Chancery of the
State of Delaware or, if such Court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or,
if jurisdiction is vested exclusively in the Federal courts of the United States, the Federal courts of the United States sitting
in the State of Delaware, and any appellate court from any such state or Federal court. Each party waives any objection it may
now or hereafter have to the laying of venue of any such Legal Proceeding, and irrevocably submits to personal jurisdiction in
any such court in any such Legal Proceeding and hereby further irrevocably and unconditionally waives and agrees not to plead
or claim in any court that any such Legal Proceeding brought in any such court has been brought in any inconvenient forum. Each
party consents to accept service of process in any such Legal Proceeding by service of a copy thereof upon either its registered
agent in the State of Delaware or the Secretary of State of the State of Delaware, with a copy delivered to it by certified or
registered mail, postage prepaid, return receipt requested, addressed to it at the address set forth in Section 13.
Nothing contained herein shall be deemed to affect the right of any party to serve process in any manner permitted by law. EACH
PARTY HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT.

 

15. Specific
Performance. Each party to this Agreement acknowledge and agree that the other party would be irreparably injured by an
actual breach of this Agreement by the first-mentioned party or its Representatives and that monetary remedies may be inadequate
to protect either party against any actual or threatened breach or continuation of any breach of this Agreement. Without prejudice
to any other rights and remedies otherwise available to the parties under this Agreement, each party shall be entitled to equitable
relief by way of injunction or otherwise and specific performance of the provisions hereof upon satisfying the requirements to
obtain such relief without the necessity of posting a bond or other security, if the other party or any of its Representatives
breach or threaten to breach any provision of this Agreement. Such remedy shall not be deemed to be the exclusive remedy for a
breach of this Agreement, but shall be in addition to all other remedies available at law or equity to the non-breaching party.

 

    12

     

    

 

16. Certain
Definitions and Interpretations. As used in this Agreement: (a) the terms “Affiliate” and “Associate”
(and any plurals thereof) have the meanings ascribed to such terms under Rule 12b-2 promulgated by the SEC under the Exchange
Act and shall include all persons or entities that at any time prior to the Termination Date become Affiliates or Associates of
any applicable person or entity referred to in this Agreement; provided, however, that the term “Associate”
shall refer only to Associates controlled by the Company or the members of the Investor Group, as applicable; provided, further,
that, for purposes of this Agreement, the members of the Investor Group shall not be Affiliates or Associates of the Company and
the Company shall not be an Affiliate or Associate of the members of the Investor Group; (b) the term “Annual Meeting”
means each annual meeting of stockholders of the Company and any adjournment, postponement, rescheduling or continuation thereof;
(c) the terms “beneficial ownership,” “group,” “participant,” “person,”
“proxy” and “solicitation” (and any plurals thereof) have the meanings ascribed to such
terms under the Exchange Act and the rules and regulations promulgated thereunder, provided, that the meaning of “solicitation”
shall be without regard to the exclusions set forth in Rules 14a-1(l)(2)(iv) and 14a-2 under the Exchange Act; (d) the term “Business
Day” means any day that is not a Saturday, Sunday or other day on which commercial banks in the State of New York are
authorized or obligated to be closed by applicable law; (e) the term “Exchange Act” means the Securities Exchange
Act of 1934, as amended, and the rules and regulations promulgated thereunder; (f) the term “Extraordinary Transaction”
means any tender offer, exchange offer, merger, consolidation, acquisition, business combination, sale, recapitalization, restructuring,
or other transaction with a third party that, in each case, that results in a change in control of the Company or the sale of
substantially all of its assets; (g) the term “Independent Director” means an individual that (i) qualifies
as an “independent director” under applicable rules of the SEC, the rules of any stock exchange on which the Company
is traded and applicable governance policies of the Company and (ii) is not an employee, principal, Affiliate or Associate of
the members of the Investor Group or any of their Affiliates or Associates; (h) the term “Net Long Position”
means such shares of Common Stock beneficially owned, directly or indirectly, that constitute such person’s net long position
as defined in Rule 14e-4 under the Exchange Act mutatis mutandis, provided that “Net Long Position” shall not
include any shares as to which such person does not have the right to vote or direct the vote other than as a result of being
in a margin account, or as to which such person has entered into a derivative or other agreement, arrangement or understanding
that hedges or transfers, in whole or in part, directly or indirectly, any of the economic consequences of ownership of such shares;
and the terms “person” or “persons,” for purposes of the meaning of the term “Net Long Position,”
shall mean any individual, corporation (including not-for-profit), general or limited partnership, limited liability or unlimited
liability company, joint venture, estate, trust, associate, organization or other entity of any kind or nature; (i) the term “Representatives”
means (i) a person’s Affiliates and Associates and (ii) its and their respective directors, officers, employees, partners,
members, managers, consultants, legal or other advisors, agents and other representatives acting in a capacity on behalf of, in
concert with or at the direction of such person or its Affiliates or Associates; (j) the term “SEC” means the
U.S. Securities and Exchange Commission; (k) the term “Short Interests” means any agreement, arrangement, understanding
or relationship, including any repurchase or similar so-called “stock borrowing” agreement or arrangement, engaged
in, directly or indirectly, by such person, the purpose or effect of which is to mitigate loss to, reduce the economic risk (of
ownership or otherwise) of shares of any class or series of the Company’s equity securities by, manage the risk of share
price changes for, or increase or decrease the voting power of, such person with respect to the shares of any class or series
of the Company’s equity securities, or that provides, directly or indirectly, the opportunity to profit from any decrease
in the price or value of the shares of any class or series of the Company’s equity securities; (l) the term “Stockholder
Meeting” means each annual or special meeting of stockholders of the Company, or any action by written consent of the
Company’s stockholders in lieu thereof, and any adjournment, postponement, rescheduling or continuation thereof; (m) the
term “Synthetic Equity Interests” means any derivative, swap or other transaction or series of transactions
engaged in, directly or indirectly, by such person, the purpose or effect of which is to give such person economic risk similar
to ownership of equity securities of any class or series of the Company, including due to the fact that the value of such derivative,
swap or other transactions are determined by reference to the price, value or volatility of any shares of any class or series
of the Company’s equity securities, or which derivative, swap or other transactions provide the opportunity to profit from
any increase in the price or value of shares of any class or series of the Company’s equity securities, without regard to
whether (i) the derivative, swap or other transactions convey any voting rights in such equity securities to such person;
(ii) the derivative, swap or other transactions are required to be, or are capable of being, settled through delivery of such
equity securities; or (iii) such person may have entered into other transactions that hedge or mitigate the economic effect of
such derivative, swap or other transactions; and (n) the term “Third Party” refers to any person that is not
a party, a member of the Board, a director or officer of the Company, or legal counsel to either party. In this Agreement, unless
a clear contrary intention appears, (i) the word “including” (in its various forms) means “including, without
limitation;” (ii) the words “hereunder,” “hereof,” “hereto” and words of similar import
are references in this Agreement as a whole and not to any particular provision of this Agreement; (iii) the word “or”
is not exclusive; (iv) references to “Sections” in this Agreement are references to Sections of this Agreement unless
otherwise indicated; and (v) whenever the context requires, the masculine gender shall include the feminine and neuter genders.

 

    13

     

    

 

 17.  Miscellaneous.

 

(a) This
Agreement, including all exhibits hereto, with the exception of the Confidentiality Agreement, contains the entire agreement between
the parties and supersedes all other prior agreements and understandings, both written and oral, between the parties with respect
to the subject matter hereof.

 

(b) This
Agreement is solely for the benefit of the parties and is not enforceable by any other persons.

 

(c) This
Agreement shall not be assignable by operation of law or otherwise by a party without the consent of the other party. Any purported
assignment without such consent is void ab initio. Subject to the foregoing sentence, this Agreement shall be binding upon,
inure to the benefit of, and be enforceable by and against the permitted successors and assigns of each party.

 

(d) Neither
the failure nor any delay by a party in exercising any right, power or privilege under this Agreement shall operate as a waiver
thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any
right, power or privilege hereunder.

 

(e) If
any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, void
or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force
and effect and shall in no way be affected, impaired or invalidated. It is hereby stipulated and declared to be the intention
of the parties that the parties would have executed the remaining terms, provisions, covenants and restrictions without including
any of such which may be hereafter declared invalid, void or unenforceable. In addition, the parties agree to use their reasonable
best efforts to agree upon and substitute a valid and enforceable term, provision, covenant or restriction for any of such that
is held invalid, void or unenforceable by a court of competent jurisdiction.

 

    14

     

    

 

(f) Any
amendment or modification of the terms and conditions set forth herein or any waiver of such terms and conditions must be agreed
to in a writing signed by each party.

 

(g) This
Agreement may be executed in one or more textually identical counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same agreement. Signatures to this Agreement transmitted by facsimile transmission,
by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic means intended
to preserve the original graphic and pictorial appearance of a document, shall have the same effect as physical delivery of the
paper document bearing the original signature.

 

(h) Each
of the parties acknowledges that it has been represented by counsel of its choice throughout all negotiations that have preceded
the execution of this Agreement, and that it has executed this Agreement with the advice of such counsel. Each party and its counsel
cooperated and participated in the drafting and preparation of this Agreement, and any and all drafts relating thereto exchanged
among the parties will be deemed the work product of all of the parties and may not be construed against any party by reason of
its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities
in this Agreement against any party that drafted or prepared it is of no application and is hereby expressly waived by each of
the parties, and any controversy over interpretations of this Agreement will be decided without regard to events of drafting or
preparation.

 

(i) The
headings set forth in this Agreement are for convenience of reference purposes only and will not affect or be deemed to affect
in any way the meaning or interpretation of this Agreement or any term or provision of this Agreement

 

[Signature
Pages Follow]

 

    15

     

    

 

IN
WITNESS WHEREOF, each of the parties has executed this Agreement, or caused the same to be executed by its duly authorized representative,
as of the date first above written.

 

	 	THE
    COMPANY:
	 	 	 
	 	KNOWLES
    CORPORATION
	 	 	 
	 	By:	/s/
    Jeffrey S. Niew
	 	Name:	Jeffrey
    S. Niew
	 	Title:	President
    and Chief Executive Officer

 

Signature
Page to Settlement Agreement

 

    

     

    

 

	 	INVESTOR GROUP:
	 	 
	 	CALIGAN
                    PARTNERS LP

	 	 
	 	

        By:
        
	/s/
    Samuel J. Merksamer
	 	Name:	Samuel J. Merksamer
	 	Title:	Partner
	 	 	 
	 	CALIGAN
                    PARTNERS CV I LP

	 	 
	 	By:
                    Caligan Partners LP, its investment manager

	 	 
		

        By:
        
	/s/ Samuel J. Merksamer 
	 	Name:	Samuel J. Merksamer
	 	Title:	Partner
	 	 	 
	 	CALIGAN
                    PARTNERS CV GP LLC

	 	 
	 	

        By:
        
	/s/
    Samuel J. Merksamer
	 	Name:	Samuel J. Merksamer
	 	Title:	Managing Member
	 	 	 
		CALIGAN
                    PARTNERS GP, LLC

	 	 
	 	

        By:
        
	/s/
    Samuel J. Merksamer
	 	Name:	Samuel J. Merksamer
	 	Title:	Managing Member
	 	 	 
	 	FALCON
                    EDGE CAPITAL, LP

	 	 
	 	

        By:
        
	/s/
    Mark Cho
	 	Name:	Mark Cho
	 	Title:	Authorized Signatory
	 	 	 
	 	FALCON
                    EDGE (CAYMAN) GP, LTD.

	 	 
	 	

        By:
        
	/s/
    Mark Cho
	 	Name:

        
	Mark Cho
	 	Title:	Authorized Signatory

 

Signature
Page to Settlement Agreement

 

    

     

    

 

	 	

FALCON
EDGE GLOBAL MASTER FUND, LP

	 	 
	 	By: Falcon Edge Capital LP, its investment
manager

	 	 
		

        By:
        
	/s/ Mark Cho
	 	Name:

        
	 Mark Cho

	 	Title:	 Authorized Signatory
	 	 	 
	 	MORAINE
                    MASTER FUND, LP

	 	 
	 	By: Falcon Edge Capital LP, its investment
manager

	 	 
	 	

        By:
        
	/s/ Mark Cho
	 	Name:	 Mark Cho

	 	Title:

        
	 Authorized Signatory
	 	 	 
	 	PATRIOT
                    GLOBAL MANAGEMENT, LP

	 	 
	 	

        By:
        
	/s/ Jonathan Christodoro
	 	Name:	 Jonathan Christodoro
	 	Title:	 Authorized Signatory
	 	 	 
	 	SAMUEL
                    J. MERKSAMER

	 	
	
		/s/ Samuel J. Merksamer
	 	 	 
	 	DAVID
                    E. JOHNSON

	 	 	 
	 	/s/ David E. Johnson
	 	 	 
	 	JONATHAN
    CHRISTODORO
	 	 	 
	 	/s/ Jonathan Christodoro
	 	 	 

 

Signature
Page to Settlement Agreement

 

    

     

    

 

Exhibit
A

 

Form
of Nomination Withdrawal

 

    

     

    

 

CALIGAN
PARTNERS CV I LP

c/o
Caligan Partners LP

520 Madison Avenue

New York, New York 10022

 

[●],
2019

Knowles
Corporation

1151
Maplewood Drive

Itasca,
Illinois 60143

Attn:
Thomas Jackson, General Counsel

 

	Re:	Withdrawal
of Stockholder Notice of Intent to Nominate Persons for Election as Directors at the 2019 Annual Meeting of Stockholders of Knowles
Corporation

 

Dear
Mr. Jackson:

 

Caligan
Partners CV I LP, a Cayman Islands exempted limited partnership (the “Record Holder”), submitted notice of
its intent to nominate persons for election as directors at the 2019 annual meeting of stockholders of Knowles Corporation, a
Delaware corporation (the “Company”) by letter dated January 30, 2019, as updated and supplemented by letter
dated March 11, 2019 (collectively, the “Notice”).

 

The
purpose of this letter is to provide the Company with notice of the Record Holder’s withdrawal of the Notice and the proposed
nominations of Samuel J. Merksamer and Jonathan Christodoro, effective immediately upon the execution of a definitive settlement
agreement among the Company, Caligan Partners LP and Falcon Edge Capital, LP and other related parties.

 

	 	Very truly yours,
	 	 	 
	 	CALIGAN PARTNERS CV I LP
	 	 	 
	 	By:	Caligan Partners LP, its investment manager
	 	 	 
	 	By:	 
	 	 	Name: Samuel J. Merksamer
	 	 	Title: Partner

 

    

     

    

 

Exhibit
B

 

Form of Designee
Agreement

 

    

     

    

 

[●],
20[●]

 

Board
of Directors

Knowles Corporation

1151 Maplewood Drive

 

Itasca,
Illinois 60143

 

Re:
Designee Agreement

 

Ladies
and Gentlemen:

 

Reference
is made to that certain Settlement Agreement (the “Agreement”), dated as of May 9, 2019, by and among Knowles
Corporation, a Delaware corporation (the “Company”), on the one hand, and Caligan Partners CV I LP, a Cayman
Islands exempted limited partnership (“Caligan CV I”), Caligan Partners LP, a Delaware limited partnership
(“Caligan”), Caligan Partners CV GP LLC, a Delaware limited liability company, Caligan Partners GP, LLC, a
Delaware limited liability company, Falcon Edge Capital, LP, a Delaware limited partnership (“Falcon Edge”),
Falcon Edge (Cayman) GP, Ltd., a Cayman Islands corporation, Falcon Edge Global Master Fund, LP, a Cayman Islands exempted limited
partnership, Moraine Master Fund, LP, a Cayman Islands exempted limited partnership, Patriot Global Management, LP, a Delaware
limited partnership, Samuel J. Merksamer, an individual, David E. Johnson, an individual, and Jonathan Christodoro, an individual
(the foregoing, together with Caligan CV I, and collectively with each of their respective Affiliates, the “Investor
Group”), on the other hand. Capitalized terms used herein but not defined shall have the meaning set forth in the Agreement.

 

		1.	If
                                         appointed or elected as a director of the Company, I hereby irrevocably offer to resign
                                         from my position as a director of the Board and from any and all committees of the Board
                                         on which I serve, subject to acceptance by the Board, effective immediately upon the
                                         Board’s notice to me that it has accepted such offer of resignation, which the
                                         Board may give within 30 business days after the Board or the chairman thereof obtains
                                         actual knowledge of any of the following: (a) the Termination Date; (b) such time as
                                         the Investor Group’s Net Long Position falls below the Ownership Minimum; (c) a
                                         material breach of the Agreement by the Investor Group that terminates the Company’s
                                         obligations to the Investor Group pursuant to Section 11(a)(ii) of the Agreement; (d)
                                         my material breach of this letter agreement; or (e) a material inaccuracy in any director
                                         questionnaire that I have submitted to the Company.

 

		2.	If
                                         elected as a director of the Company, I agree to comply with the terms of the Company’s
                                         Certificate of Incorporation (as amended and as may be further amended from time to time),
                                         By-Laws (as amended and as may be further amended from time to time), committee charters,
                                         corporate governance, ethics, conflict of interest, confidentiality, stock ownership
                                         and trading policies and guidelines and similar governance documents that are generally
                                         applicable to the Company’s directors; provided, that in the event of a
                                         conflict between this letter agreement and the terms of the Confidentiality Agreement,
                                         the terms of the Confidentiality Agreement shall control; and provided, further,
                                         that the Reimbursement Agreement, dated as of May 9, 2019, by and among Caligan and Falcon
                                         Edge, on the one hand, and me, on the other hand, and its terms, in the form executed
                                         by the parties thereto and provided to the Company prior to the execution and delivery
                                         hereof, shall not be deemed to constitute a breach or violation of this paragraph 2.

    1

     

    

 

		3.	I
                                         agree that, during the term of the Agreement, the Board or any committee thereof, in
                                         the exercise of its fiduciary duties, may recuse me from any portion of a Board or committee
                                         meeting, and restrict my access to information of the Company, to the extent relating
                                         to (a) the Agreement, including the interpretation and enforcement thereof, (b) any demand
                                         made by any member of the Investor Group or any of their respective Affiliates if such
                                         demand is coupled, expressly or implied, with the threat to take any of the actions prohibited
                                         in Sections 3(a) through 3(l) of the Agreement, (c) this letter agreement, (d) my failure
                                         to comply with the Charter, the By-Laws or policies that are applicable to all directors
                                         or (e) any proposed transaction between the Company and any member of the Investor Group
                                         or any of their respective Affiliates. I further agree that, during the term of the Agreement,
                                         (i) consistent with my fiduciary duties as a director of the Company, I shall consider
                                         in good faith, to the same extent as any other director of the Company, recusal from
                                         any Board or committee meeting in the event there is any other actual or potential conflict
                                         of interest between the Investor Group or myself, on the one hand, and the Company, on
                                         the other hand; and (ii) the Board may restrict my access to information of the Company
                                         to the same extent it would for any other director of the Company, in accordance with
                                         applicable law.

 

		4.	I
                                         agree that, during the term of the Agreement, there shall be no contracts, plans or arrangements,
                                         written or otherwise, in effect during the term of the Agreement, between any members
                                         of the Investor Group and myself, providing for any compensation, reimbursement of expenses
                                         or indemnification of me in connection with or related to my service on the Board, other
                                         than the Reimbursement Agreement.

 

		5.	Each
                                         party hereto acknowledges and agrees that, for so long as I am serving as a director
                                         on the Board, I may provide Confidential Information to the members of the Investor Group
                                         and their Representatives; provided, however, that the Investor Group and I shall
                                         have executed a Confidentiality Agreement with the Company prior to any provision of
                                         Confidential Information to the members of the Investor Group or their Representatives
                                         by me. For the avoidance of doubt, each party hereto further acknowledges and agrees
                                         that the obligations under this letter agreement shall be in addition to, and not in
                                         lieu of, my confidentiality obligations under Delaware law and the Charter, By-Laws and
                                         applicable corporate governance policies of the Company; provided, however
                                         that in the event of a conflict between my confidentiality obligations under the
                                         committee charters, corporate governance, confidentiality, and similar governance documents
                                         and governance policies of the Company and those in the Confidentiality Agreement, the
                                         terms of the Confidentiality Agreement shall control.

 

		6.	The
                                         Company shall provide me with the same compensation, including without limitation restricted
                                         stock units, shares of capital stock, and other equity equivalents, and including any
                                         initial stock grant and all subsequent stock grants, on the same terms and subject to
                                         the same conditions, as is provided to (a) any other member of the Board (other than
                                         the chairman) in consideration for such member’s service as such, and (b) any member
                                         of any Board committee of which I am or may become a member. The Company shall reimburse
                                         my expenses incurred in connection with or related to my service on the Board on the
                                         same terms and subject to the same conditions and policies as are applicable to Board
                                         members generally.

 

		7.	This
                                         letter agreement, and any disputes arising out of or related to this letter agreement
                                         (whether for breach of contract, tortious conduct or otherwise), shall be governed by,
                                         and construed in accordance with, the laws of the State of Delaware, without giving effect
                                         to its conflict of laws principles.

 

		8.	Each
                                         party hereto acknowledges and agrees that the other party would be irreparably injured
                                         by an actual breach of this letter agreement by the first-mentioned party and that monetary
                                         remedies may be inadequate to protect either party against any actual or threatened breach
                                         or continuation of any breach of this letter agreement. Without prejudice to any other
                                         rights and remedies otherwise available to the parties under this letter agreement, each
                                         party shall be entitled to equitable relief by way of injunction or otherwise and specific
                                         performance of the provisions hereof upon satisfying the requirements to obtain such
                                         relief without the necessity of posting a bond or other security, if the other party
                                         breaches or threaten to breach any provision of this letter agreement. The parties agree
                                         that specific performance shall be the sole and specific remedy for a breach of this
                                         letter agreement; provided that in the event of litigation relating to this letter
                                         agreement, if a court of competent jurisdiction determines that a party has breached
                                         this letter agreement, then such breaching party shall be liable for, and shall pay,
                                         the reasonable legal fees, costs and expenses that the non-breaching party has incurred
                                         in connection with such litigation, including any appeal therefrom; provided, further,
                                         that in the event of litigation related to this letter agreement, if a court of competent
                                         jurisdiction does not make a determination that a party has breached this letter agreement,
                                         then the party who claimed that such breach occurred shall be liable for, and shall pay,
                                         the reasonable legal fees, costs and expenses that the other party has incurred in connection
                                         with such litigation, including any appeal therefrom. For the avoidance of doubt, nothing
                                         in this letter agreement is intended to limit remedies available against any party for
                                         a breach of applicable law or regulation by such party.

 

		9.	Neither
                                         the failure nor any delay by a party in exercising any right, power or privilege under
                                         this letter agreement shall operate as a waiver thereof, nor shall any single or partial
                                         exercise thereof preclude any other or further exercise thereof or the exercise of any
                                         right, power or privilege hereunder.

 

    2

     

    

 

		10.	This
                                         letter agreement and the obligations hereunder shall terminate on the date that I am
                                         no longer a director of the Board, without affecting any rights, remedies or obligations
                                         arising or accruing prior to such date.

 

		11.	If
                                         any term, provision, covenant or restriction of this letter agreement is held by a court
                                         of competent jurisdiction to be invalid, void or unenforceable, the remainder of the
                                         terms, provisions, covenants and restrictions of this letter agreement shall remain in
                                         full force and effect and shall in no way be affected, impaired or invalidated. It is
                                         hereby stipulated and declared to be the intention of the parties hereto that the parties
                                         would have executed the remaining terms, provisions, covenants and restrictions without
                                         including any of such which may be hereafter declared invalid, void or unenforceable.
                                         In addition, the parties agree to use their reasonable best efforts to agree upon and
                                         substitute a valid and enforceable term, provision, covenant or restriction for any of
                                         such that is held invalid, void or unenforceable by a court of competent jurisdiction.

 

[Remainder of
page intentionally left blank]

 

    3

     

    

 

	 	Very Truly Yours,
	 	 
	 	 
	 	Name:
	 	Address: 

 

	Accepted and Agreed by:	 
	 	 
	KNOWLES CORPORATION	 
	 	 
	 	 
	By: 	 
	Title:	 

 

 

 

SIGNATURE PAGE TO DESIGNEE AGREEMENT

 

    

     

    

 

Exhibit
C

 

Form of Reimbursement Agreement

 

    

     

    

 

EXECUTION
VERSION

 

REIMBURSEMENT
AGREEMENT

 

1.
This Reimbursement Agreement (the “Agreement”), dated May [●], 2019, is by and among Caligan Partners, L.P. (“Caligan”),
Falcon Edge Capital LP (“Falcon Edge,” and together with Caligan, the “Investor Group,” “we” or
“us”), on the one hand, and Steven F. Mayer (“you”), on the other hand.

 

2.
In connection with the settlement agreement by and among the Knowles Corporation (“Knowles” or the “Company”),
the Investor Group, and the other parties thereto (the “Settlement Agreement”), the confidentiality agreement between
Knowles Corporation and the Investor Group (the “Confidentiality Agreement”) and your appointment to the Board of Directors
of the Company (the “Board”) as an independent director, in the event that you incur any reasonable documented expenses,
including without limitation travel expenses, in connection with your service in such capacity prior to the Termination Date (as
defined in the Settlement Agreement), including without limitation in connection with your provision of confidential information
to us pursuant to the terms of the Settlement Agreement, and whether such expenses are incurred prior to or after the execution
and delivery of this Agreement, we jointly and severally agree to reimburse you for such expenses, promptly upon submission of
such documentation to us, to the extent not reimbursed by the Company.

 

3.
In the event that (i) you are required by the Company to resign from the Board pursuant to the Settlement Agreement other than
(a) as a result of your material breach of an obligation to the Company binding on you, or (b) as a result of a material misrepresentation
or omission in your director questionnaire, and the Board accepts such resignation, or (ii) your board membership terminates for
any other reason, other than (c) as a result of your death, disability or incapacity, or (d) as a result of your voluntary resignation
(it being understood that the fact that you have signed and delivered to the Company an undated resignation letter, which the
Company may thereafter accept, does not in and of itself constitute any resignation as being voluntary), and as a result of any
such accepted resignation or termination (other than as provided in clauses (a) through (d) above) any awarded but unvested shares
of common stock of the Company, par value $0.01 per share, or any related restricted stock units or similar equity-based compensation,
are forfeited or will not vest, then we jointly and severally agree to reimburse you an amount equal to the value of such awarded
but unvested shares, units or compensation (based on the average closing price of the common stock on the previous five trading
days prior to such resignation or termination).

 

    

     

    

 

4.
The Investor Group, jointly and severally, agrees that, in the event and to the extent that indemnification is not available,
or claimed to be not available, to you under the Company’s Amended and Restated Certificate of Incorporation, as amended, the
Company’s Amended and Restated Bylaws, or the Company’s director & officer insurance policy, and/or in the event and to the
extent that any such indemnification is not sufficient to hold you harmless, the Investor Group will, jointly and severally, indemnify
and hold you harmless from and against any and all losses, liabilities, claims, actions, threatened actions, judgments, and reasonable
costs, expenses, and disbursements (including without limitation reasonable attorneys’ fees and expenses) (“Losses”)
incurred by you in connection with or arising out of your nomination by us as a member of the Board, your service on the Board,
your provision of confidential information to us pursuant to the terms of the Settlement Agreement, the other matters contemplated
by this Agreement, your enforcement of your claim or right to indemnification or to advances of expenses as a director in connection
with your service as a director prior to the Termination Date (as defined in the Settlement Agreement), or your enforcement of
this Agreement; provided, however, that the aggregate amount of indemnification available under this paragraph shall not exceed
$5,000,000, and the Investor Group shall not be liable for any Losses in excess of such amount (in the aggregate). Your right
of indemnification hereunder shall continue after the Termination Date has taken place, but only for acts, omissions, or circumstances
that occurred, or claims based on matters arising or alleged to have arisen, prior to the Termination Date. Your right of indemnification
will not apply to the extent the Losses are otherwise paid under any directors and officers or other insurance policy that may
separately provide coverage to you as a director of the Company or otherwise. Nothing herein shall be construed to provide you
with indemnification against Losses to the extent that such Losses were caused by (i) a material breach or violation by you of
the Settlement Agreement or the Governance Compliance Agreement (as defined in the Settlement Agreement); (ii) your violation
of any provision of state or federal law, unless you demonstrate that your action was taken in good faith; or (iii) actions or
omissions by you that constitute bad faith, gross negligence or willful misconduct. You shall promptly notify the Investor Group
in writing in the event of any claims for which you seek indemnification hereunder, and thereafter the Investor Group shall advance
to you your reasonable legal fees and expenses in connection therewith to the extent that no such advances have been received
by you from the Company or any insurer related thereto, provided that the Investor Group may require, as a condition to such advances,
that you execute an undertaking to repay such advances if it is ultimately determined, in a final and binding judicial decision,
that you were not entitled to the indemnification to which such advances related. The Investor Group’s indemnification obligations
will be deemed (as between the Investor Group and the Company) secondary to any insurance or indemnification provided by the Company
to its directors, and (to the extent that the Company’s director indemnification policies and insurance coverage would cover the
Losses in question in the absence of this Agreement) the Company will be deemed for all purposes to be the primary obligor with
respect to any and all such Losses sustained for which the Investor Group otherwise would be required to indemnify you pursuant
to this paragraph 4.

 

5.
Each of us recognizes that should you be elected or appointed to the Board all of your activities and decisions as a director
will be governed by applicable law and subject to your fiduciary duties, as applicable, to the Company and to the stockholders
of the Company and, as a result, that there is, and can be, no agreement between you and the Investor Group that governs the decisions
which you will make as a director of the Company.

 

6.
We hereby jointly and severally represent and warrant that attached hereto are true and correct copies of the Settlement Agreement,
the Confidentiality Agreement, and the Governance Compliance Agreement.

 

7.
This Agreement shall automatically terminate on the earliest to occur of (i) the Termination Date and (ii) the date you cease
to serve as a member of the Board; provided, however, that the third, fourth, eighth, ninth and tenth paragraphs of this Agreement
shall survive such termination; and provided, further, that no termination of this Agreement shall affect any rights or obligations
of the parties arising or accrued prior to such termination.

 

    

     

    

 

8.
This Agreement may be executed in counterparts with the same effect as though all parties had signed the same document. All counterparts
shall be construed together and shall constitute one agreement. A signed pdf, fax or photocopy of this Agreement shall be as valid
as an original.

 

9.
This Agreement sets forth the entire agreement between the Investor Group and you as to the subject matter contained herein, and
cannot be amended, modified or terminated except by a writing executed by each member of the Investor Group and you.

 

10.
This Agreement shall be governed by the laws of the State of New York, without regard to the principles of the conflicts of laws
thereof. The parties agree to the exclusive jurisdiction of the state and federal courts of New York, New York, and waive, and
agree not to plead or to make, any claim that any action or proceeding brought in the state and federal courts of New York, New
York has been brought in an improper or inconvenient forum.

 

[Signature
Page Follows]

 

    

     

    

 

Agreed
to as of the date first set forth above:

 

	THE INVESTOR GROUP:	 
	 	 	 
	CALIGAN PARTNERS, L.P.	 
	 	 	 
	By:	        	 
	Name:  Samuel Merksamer	 
	Title:  Partner	 
	 	 	 
	FALCON EDGE CAPITAL, LP	 
	 	 	 
	By:	 	 
	Name:  Mark Cho	 
	Title:  Authorized Signatory	 
	 	 	 
	STEVEN F. MAYER:	 
	 	 	 
	 	 
	Name:  Steven F. Mayer	 

 

 

    

     

    

 

Exhibit
D

 

Form
of Press Release

 

    

     

    

  

FOR
IMMEDIATE RELEASE

 

Knowles
Announces Agreement with Caligan Partners, Falcon Edge Capital and 

Patriot Global Management; Steven F. Mayer Added to Board of
Directors

 

Knowles
to Host Analyst Day in the Fall of 2019 

 

ITASCA,
Ill.—May [●], 2019— Knowles Corporation (NYSE: KN), a market leader and global provider of advanced micro-acoustic,
audio processing and precision device solutions, today announced that it has entered into a Settlement Agreement with Caligan
Partners, LP, Falcon Edge Capital, LP and Patriot Global Management, LP (the “Group”). As part of this agreement,
the Board of Directors will add Steven F. Mayer to the Knowles Board effective immediately. Mr. Mayer will also stand for election
at the 2019 Annual Meeting. Mr. Mayer's appointment will expand the Knowles Board to 10 directors, nine of whom are independent
and five of whom will have been appointed in the last four years.

 

In
addition, the Governance and Nominating Committee of the Knowles Board and the Group will search for an additional mutually agreed
upon independent director to be identified next year. Furthermore, following approval at the 2018 Annual Meeting of Shareholders,
the Knowles Board will continue its process of phased declassification beginning at the 2019 Annual Meeting and concluding at
the 2021 Annual Meeting of Shareholders, after which the entire Board will stand for election annually. The Knowles Board also
continues to unanimously recommend that shareholders vote in favor of proposals at the 2019 Annual Meeting to eliminate the supermajority
vote requirements for amending the Company’s governance documents.

 

“The
Knowles Board is committed to best-in-class governance and we are pleased to add Steve as a new independent director along with
our other experienced and highly qualified nominees,” said Donald Macleod, Chairman of the Knowles Board. “We look
forward to working together to drive sustainable growth and enhance value for all Knowles shareholders.”

 

“Knowles
is the market leader in micro-acoustic components and high-reliability ceramic capacitors and filters, with a rich history of
innovation. We look forward to working constructively with Steve and the Knowles Board to help the Company achieve its substantial
potential,” said a spokesperson for the Group.

 

Knowles
has entered into an agreement with the Group under which the Group has agreed to withdraw its slate of director nominees and vote
all of its shares in support of Knowles’ full slate of directors at the Company’s 2019 Annual Meeting. Additionally,
the Group has agreed to customary standstill and other provisions. The full agreement will be filed on Form 8-K with the U.S.
Securities and Exchange Commission (SEC).

 

Knowles
plans to file with the SEC a supplement to its definitive proxy statement, accompanied by a revised WHITE proxy card on which
Knowles shareholders can vote to elect the Company’s four director nominees, including Mr. Mayer. Knowles shareholders who
previously voted may change their vote by executing a WHITE proxy card or by voting by telephone or through the Internet by following
the instructions shown on the WHITE proxy card. Only the latest dated proxy submitted will be counted.

 

J.P.
Morgan is serving as Knowles’ financial advisor and Sidley Austin LLP is serving as the Company’s legal advisor. Schulte,
Roth & Zabel is representing the Group.

 

2019
Analyst Day

 

Knowles
also announced today that it plans to host an Analyst Day in the fall of 2019. Specific details will be provided at a later date.

 

    

     

    

 

About
Steven F. Mayer

 

Steven
Mayer is the Chief Executive Officer of Iron Horse Acquisition Corp. and Dedication Capital, LLC, privately held investment vehicles.
From 2002 until 2018, he held a variety of senior positions with Cerberus Capital Management, L.P. and Cerberus California, LLC,
affiliated private investment firms, most recently serving as Senior Managing Director, Co-Head of Global Private Equity, and
Chairman of the Cerberus Investment Committee.

 

Previously,
Mr. Mayer was an executive managing director of Gores Technology Group, a private equity investment firm that acquires controlling
interests in and manages underperforming and non-core technology and telecommunications companies. Prior to joining Gores, Mr.
Mayer served as a managing director of Libra Capital Partners, L.P. and Aries Capital Group, LLC, and was a principal with Apollo
Advisors, L.P. and Lion Advisors, L.P., affiliated private equity investment firms. Prior to that time, Mr. Mayer was an attorney
with Sullivan & Cromwell specializing in mergers, acquisitions, divestitures, leveraged buyouts and corporate finance.

 

Mr.
Mayer has served as a member of the board of directors or equivalent body of a large number of companies in a wide variety of
industries in the United States and Europe, and is currently a member of the Board of Directors of Grifols, S.A. and the Board
of Supervisors of Syntellix AG.

 

Mr.
Mayer holds a Bachelor in Arts from Princeton University and a Degree in Law (JD, Juris Doctor) from Harvard Law School.

 

About
Knowles:

 

Knowles
Corporation (NYSE: KN) is a market leader and global provider of advanced micro-acoustic, audio processing, and precision device
solutions, serving the mobile consumer electronics, communications, medical, defense, automotive, and industrial markets. Knowles
uses its leading position in MEMS (micro-electro-mechanical systems) microphones and strong capabilities in audio processing technologies
to optimize audio systems and improve the user experience in mobile, ear, and IoT applications. Knowles is also the leader in
acoustic components, high-end capacitors, and mmWave RF solutions for a diverse set of markets. Knowles’ focus on the customer,
combined with unique technology, proprietary manufacturing techniques, rigorous testing, and global scale, enables it to deliver
innovative solutions that optimize the user experience. Founded in 1946 and headquartered in Itasca, Illinois, Knowles is a global
organization with employees in 11 countries. The company was spun out from Dover Corporation in 2014 and has been focused on reshaping
its business portfolio and investing in high value solutions to diversify its revenue and increase exposure to high-growth markets.
For more information, visit knowles.com.

 

Forward
Looking Statements

 

This
news release contains forward-looking statements within the meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project,”
“estimate,” “budget,” “continue,” “could,” “intend,” “may,”
“plan,” “potential,” “predict,” “seek,” “should,” “will,”
“would,” “objective,” “forecast,” “goal,” “guidance,” “outlook,”
“effort,” “target,” and similar expressions, among others, generally identify forward-looking statements,
which speak only as of the date the statements were made. The statements in this news release are based on currently available
information and the current expectations, forecasts, and assumptions of Knowles' management concerning risks and uncertainties
that could cause actual outcomes or results to differ materially from those outcomes or results that are projected, anticipated,
or implied in these statements. These risks and uncertainties include, but are not limited to: unforeseen changes in MEMS microphone
demand from our largest customers, in particular, two North American, a Korean, and Chinese OEM customers; the success and rate
of multi-microphone and smart microphone adoption and proliferation of our “intelligent audio” solutions, including
our audio edge processors, to high volume platforms; our ongoing ability to execute our strategy to diversify our end markets
and customers; our ability to stem or overcome price erosion in our segments; fluctuations in our stock's market price; fluctuations
in operating results and cash flows; our ability to prevent or identify quality issues in our products or to promptly remedy any
such issues that are identified; the timing of OEM product launches; risks associated with increasing our inventories in advance
of anticipated orders by customers; macroeconomic conditions, both in the U.S. and internationally; the impact of changes to laws
and regulations that affect the Company’s ability to offer products or services to customers in different regions; risks
associated with shareholder activism, including proxy contests; our ability to achieve continued reductions in our operating expenses;
our ability to obtain, enforce, defend or monetize our intellectual property rights; increases in the costs of critical raw materials
and components; availability of raw materials and components; managing new product ramps and introductions for our customers;
our dependence on a limited number of large customers; our ability to maintain and expand our existing relationships with leading
OEMs in order to maintain and increase our revenue; increasing competition and new entrants in the market for our products; our
ability to develop new or enhanced products or technologies in a timely manner that achieve market acceptance; our reliance on
third parties to manufacture, assemble, and test our products and sub-components; government trade restrictions and import/export
controls; financial risks, including risks relating to currency fluctuations, credit risks and fluctuations in the market value
of the Company; and changes in tax laws, changes in tax rates and exposure to additional tax liabilities; and other risks, relevant
factors, and uncertainties identified in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, subsequent
Reports on Forms 10-Q and 8-K and our other filings we make with the U.S. Securities and Exchange Commission (the “SEC”).
Knowles disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.

 

    

     

    

 

Important
Additional Information and Where to Find It

 

The
Company has filed a definitive a proxy statement on Schedule 14A and accompanying WHITE proxy card with the SEC in connection
with the solicitation of proxies for its 2019 Annual Meeting of Shareholders (the “Definitive Proxy Statement”). SHAREHOLDERS
ARE STRONGLY ADVISED TO READ THE COMPANY’S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO)
AND ANY OTHER DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders
may obtain a free copy of the Definitive Proxy Statement and accompanying WHITE proxy card, any amendments or supplements to the
Definitive Proxy Statement and other documents that the Company files with the SEC from the SEC’s website at www.sec.gov
or the Company’s website at www.investor.knowles.com as soon as reasonably practicable after such materials are electronically
filed with, or furnished to, the SEC.

 

Contact:

 

Mike
Knapp

Investor
Relations

Phone:
(630) 238-5236

Email:
Mike.Knapp@knowles.com

 

Media:

 

Matthew
Sherman / Nicholas Lamplough / Mahmoud Siddig

Joele Frank, Wilkinson, Brimmer, Katcher 

(212) 355-4449

 

    

     

    

 

Exhibit
E

 

Form
of Confidentiality Agreement

 

    

     

    

 

Knowles Corporation

1151 Maplewood Drive

Itasca, Illinois 60143

 

 [•],
2019

 

Caligan Partners LP

Caligan Partners CV I LP

Caligan Partners CV GP LLC

Caligan Partners GP, LLC

Samuel J. Merksamer

David E. Johnson

520 Madison Avenue

New York, NY 10022

 

Falcon Edge Capital, LP

Falcon Edge (Cayman) GP, Ltd.

Falcon Edge Global Master Fund, LP

Moraine Master Fund, LP

Patriot Global Management, LP

Jonathan Christodoro

660 Madison Avenue, 19th Floor

New York, NY 10065

 

Steven F. Mayer

11812 San Vincente Boulevard, Suite 300

Los Angeles, CA 90049

 

Re:     Confidentiality Agreement

 

Ladies and Gentlemen:

 

This letter agreement shall become effective
upon the appointment of Steven F. Mayer (the “Investor Group Designee”) to the Board of Directors (the “Board”)
of Knowles Corporation, a Delaware corporation (the “Company”), pursuant to the Settlement Agreement, dated
as of May 9, 2019 (the “Settlement Agreement”), by and among the Company, on the one hand, and Caligan Partners
CV I LP, a Cayman Islands exempted limited partnership (“Caligan CV I”), Caligan Partners LP, a Delaware limited
partnership, Caligan Partners CV GP LLC, a Delaware limited liability company, Caligan Partners GP, LLC, a Delaware limited liability
company, Falcon Edge Capital, LP, a Delaware limited partnership, Falcon Edge (Cayman) GP, Ltd., a Cayman Islands corporation,
Falcon Edge Global Master Fund, LP, a Cayman Islands exempted limited partnership, Moraine Master Fund, LP, a Cayman Islands exempted
limited partnership, Patriot Global Management, LP, a Delaware limited partnership, Samuel J. Merksamer, an individual, David E.
Johnson, an individual, and Jonathan Christodoro, an individual (the foregoing, together with Caligan CV I, and collectively with
each of their respective Affiliates, the “Investor Group”), on the other hand. Capitalized terms used and not
otherwise defined herein have the meanings given to such terms in the Settlement Agreement. For the avoidance of doubt, the Investor
Group Designee shall not be deemed part of, or to have the rights or obligations of, or to be a Representative of, the Investor
Group for purposes of this letter agreement.

 

    

     

    

 

Upon the terms of, and subject to the conditions
in, this letter agreement, the Investor Group and its Representatives may receive certain Confidential Information (as defined
herein) about the Company and its Affiliates from the Investor Group Designee or his Replacement Designee (in either case, the
“Investor Group Director”) obtained in his or her capacity as a director of the Company that is confidential
or proprietary, the disclosure of which could harm the Company or its Affiliates. The Company understands and agrees that, upon
the terms of, and subject to the conditions in, this letter agreement, the Investor Group Director may disclose Confidential Information
to the Investor Group or its Representatives, and that such disclosure on the terms of, and subject to the conditions in, this
letter agreement shall not constitute a breach of or failure to comply with the Company’s Certificate of Incorporation (as
amended and as may be further amended from time to time), By-Laws (as amended and as may be further amended from time to time),
committee charters, corporate governance, ethics, conflict of interest, confidentiality, and similar governance documents that
are generally applicable to the Company’s directors.

 

		1.	The Investor Group Director and the Investor Group understand and agree that the Investor Group
Director, when acting in his or her capacity as a director of the Company, shall be subject in all cases to the fiduciary duties
owed to the Company and its stockholders imposed by Delaware law. It is understood and agreed that the Investor Group Director
shall not disclose to the Investor Group or its Representatives (a) any confidential or proprietary information of any third
party in the possession of the Company or any of its Affiliates for which the Investor Group Director has actual knowledge, prior
to such disclosure, that the Company or any of its Affiliates is prohibited from disclosing pursuant to a contractual, fiduciary
or other legal obligation or duty of confidentiality; and (b) any legal advice or information that is specifically identified
to the Investor Group Director, prior to such disclosure, as protected by the Company’s or any of its Affiliates’ attorney-client
privilege, attorney work-product privilege or any other applicable privilege (both with respect to internal or external legal counsel).
Accordingly, and in furtherance of the foregoing, the Investor Group agrees not to claim or contend that the Company has waived
any attorney client privilege, work product doctrine or any other applicable privilege by permitting the proffer of information
pursuant to this letter agreement. The Company shall, as promptly as reasonably possible and in good faith, respond to any request
by the Investor Group Director for advice as to whether any particular Confidential Information is not to be disclosed by the Investor
Group Director in accordance with clause (a) or (b) above, or otherwise in accordance with applicable law, and the Investor Group
Director may, but shall not be required to, rely on such advice for purposes of this Section 1. The term “Representatives”
shall mean (i) with respect to the Company, members of the Board, officers, financial advisers and attorneys and (ii) with respect
to the Investor Group, any of its controlled affiliates and its and their partners, directors, officers or employees, attorneys,
accountants and financial and other advisers (excluding, for the avoidance of doubt, any member of the Board).

 

    2

     

    

 

		2.	For purposes of this letter agreement, the term “Confidential Information” includes
all information concerning or relating to the Company that is furnished directly or indirectly by the Company or any of its Representatives
prior to the termination of this letter agreement, whether or not marked as confidential, whether furnished before or after the
date of the Agreement, whether oral, written or electronic, and regardless of the manner in which it is furnished, together with
any notes, reports, summaries, analyses, compilations, forecasts, studies, interpretations, memoranda or other materials that contain,
reference, reflect or are based upon, in whole or in part, any such information. The term “Confidential Information”
does not include information that (a) was within the Investor Group’s or any of its Representatives’ possession
prior to it being furnished to the Investor Group Director by the Company or its Representatives; (b) is or becomes available
to the Investor Group or its Representatives from a source other than the Company or its Representatives; (c) is or becomes
generally available to the public; or (d) has been or is independently developed by the Investor Group or its Representatives
without the use of the Confidential Information or in violation of the terms of this letter agreement; provided that, in
the case of (a), (b) and (c), such information was not known by the Investor Group or its Representatives to have been provided
in violation of any contractual, fiduciary or other legal obligation of confidentiality owed to the Company or an Affiliate thereof
and in the case of (b) and (c), such information becomes available other than as a result of a disclosure by the Investor Group
or its Representatives in violation of this letter agreement or in violation of any other confidentiality or non-use obligations.
Notwithstanding the foregoing, specific aspects or details of Confidential Information shall not be deemed to be within the public
domain or in the Investor Group’s possession on a non-confidential basis merely because Confidential Information is embraced
by more general information in the public domain or in the Investor Group’s possession prior to the date hereof. Further,
any combination of Confidential Information shall not be considered in the public domain or in the Investor Group’s possession
on a non-confidential basis merely because individual elements of such Confidential Information are in the public domain or are
in Investor Group’s possession prior to the date hereof.

 

		3.	As a condition to the Investor Group or any of its Representatives being furnished with the Confidential
Information, the Investor Group agrees to treat as confidential, and to instruct its Representatives to treat as confidential,
any Confidential Information that is furnished to the Investor Group or its Representatives by or on behalf of the Investor Group
Director, the Company or its Representatives in accordance with the provisions of this letter agreement, and to take or abstain
from taking, and to instruct its Representatives to take or abstain from taking, certain other actions as set forth herein. The
Investor Group further agrees that it shall use the Confidential Information solely for the purpose of monitoring and evaluating
the Investor Group’s investment in the Company; provided, however, that the Investor Group may disclose the
Confidential Information (a) to any of its Representatives who need to know such information for the purpose of monitoring
and evaluating their investment in the Company or (b) as the Company may otherwise consent in writing. The Investor Group
shall (i) inform any such Representative of the confidential nature of the Confidential Information and (ii) direct such Representative
to keep the Confidential Information strictly confidential according to the terms of this letter agreement. The Investor Group
agrees to be responsible for any breaches of any of the provisions of this letter agreement by any of its Representatives as if
they were a party hereto (it being understood that such responsibility shall be in addition to and not by way of limitation of
any right or remedy the Company may have against the Investor Group’s Representatives with respect to such breach).

 

    3

     

    

 

		4.	The Investor Group hereby acknowledges that it is aware (and the Investor Group shall also advise
each of its Representatives that is provided Confidential Information) (a) of its obligations under U.S. securities laws and regulations,
(b) that the Confidential Information may contain material non-public information concerning the Company and (c) that U.S. securities
laws and regulations may restrict any person who has material, non-public information concerning an issuer from purchasing or selling
securities of such issuer or communicating such information to any other person under circumstances in which it is reasonably foreseeable
that such person is likely to purchase or sell such securities. The Investor Group agrees that it and its Representatives in possession
of material non-public information concerning the Company shall refrain from trading in the securities of the Company in violation
of U.S. securities laws and regulations while in possession of any such material non-public information. Each of the Company and
the Investor Group further acknowledges its respective acknowledgements and obligations as well as those of its Representatives
(as applicable) under Section 8 of the Settlement Agreement.

 

		5.	Notwithstanding anything to the contrary provided in this letter agreement, in the event the Investor
Group or any of its Representatives receives a request or is required by deposition, interrogatory, request for documents, subpoena,
court order, similar judicial process, civil investigative demand or similar process or pursuant to a request from a regulatory
examiner (any such requested or required disclosure, an “External Demand”) or is otherwise required pursuant
to applicable law, regulation or the rules of any governmental, national securities exchange or other regulatory authority to disclose
all or any part of the Confidential Information (as determined based on the advice of outside legal counsel), the Investor Group
agrees, and agrees to instruct its Representatives, to the extent permitted by applicable law, (a) to promptly notify the
Company of the existence, terms and circumstances surrounding such External Demand or other requirement and (b) to cooperate with
the Company in seeking a protective order or other appropriate remedy to the extent available under the circumstances. In the event
that such protective order or other remedy is not obtained or not available or that the Company waives compliance with the provisions
hereof, the Investor Group or its Representatives, as the case may be, (i) may disclose only that portion of the Confidential Information
which the Investor Group or its Representatives are advised by outside legal counsel, is legally required to be disclosed, (ii)
shall inform the recipient of such Confidential Information of the existence of this letter agreement and the confidential nature
of such Confidential Information and (iii) shall exercise reasonable efforts to obtain assurances that confidential treatment will
be accorded to the Confidential Information. For the avoidance of doubt, it is understood and agreed that there shall be no “applicable
law,” “regulation” or “rule” requiring the Investor Group or its Representatives to disclose any
Confidential Information solely by virtue of the fact that, absent such disclosure, the Investor Group or its Representatives would
be prohibited from purchasing, selling or engaging in derivative or other voluntary transactions with respect to the securities
of the Company or the Investor Group or its Representatives would be unable to file any proxy materials or tender or exchange offer
materials in compliance with Section 14 of the Exchange Act or the rules promulgated thereunder. It is further understood that
following the Termination Date and subject to the terms and conditions herein, nothing contained in this letter agreement (including,
without limitation, Section 3 of this letter agreement) shall in and of itself prevent the Investor Group or its Representatives
from (i) nominating any person to serve as a director of the Company or from proposing any other business or (ii) engaging in any
solicitation of proxies or consents or becoming a “participant” in a “solicitation” (as such terms are
defined in Regulation 14A under the Exchange Act) of proxies or consents with respect to securities of the Company; provided,
however, that (A) in taking any of the foregoing actions, the Investor Group or its Representatives will treat all Confidential
Information in accordance with the provisions of this letter agreement, and (B) the Investor Group acknowledges that Section 3
of the Settlement Agreement prohibits the foregoing actions.

 

    4

     

    

 

		6.	Within 10 days following the termination of this letter agreement in accordance with its terms
and at the Investor Group’s option, the Investor Group and its Representatives shall either promptly (a) destroy the Confidential
Information and any copies thereof or (b) return to the Company all Confidential Information and any copies thereof, and in either
case, certify in writing to the Company that all such material has been destroyed or returned, as applicable, in compliance with
this letter agreement; provided, however, that the Investor Group and its Representatives shall be permitted to retain
Confidential Information to the extent necessary to comply with applicable law, professional standards or the Investor Group or
its Representatives’ document retention policies of general application, or to the extent disclosed pursuant to an External
Demand. To the extent any Confidential Information is retained pursuant to the preceding sentence, the Investor Group and its Representatives
shall continue to be bound by the obligations contained herein with respect to such Confidential Information retained by the Investor
Group or its Representatives for such period of time as prescribed by this letter agreement.

 

		7.	During the term of this letter agreement and continuing for a period of 18 months following the
termination of this letter agreement, the Investor Group and its Representatives shall not, without the prior written approval
of the Board, directly or indirectly, for the Investor Group or on behalf of, or in conjunction with, any other person or entity
of any nature, solicit, canvass, approach, or induce any employee or contractor of the Company to terminate his, her or its employment
or engagement with the Company or any of its Affiliates or Associates, other than by means of a general advertisement that is not
directed at any particular employee or contractor of the Company.

 

		8.	The Investor Group agrees that it shall, at the Investor Group’s sole expense, use its reasonable
best efforts to undertake all measures necessary or appropriate, including, without limitation, court proceedings, (a) to restrain
the Investor Group’s Representatives from prohibited or unauthorized disclosure or use of any Confidential Information and
(b) to safeguard and protect the confidentiality of the Confidential Information disclosed to the Investor Group or any of its
Representatives and to prevent the use of any Confidential Information in any way that would violate any applicable law or this
letter agreement. The Investor Group shall notify the Company promptly, in writing, of any misuse, misappropriation or unauthorized
disclosure of any Confidential Information which may come to the Investor Group’s attention. The Investor Group shall be
responsible for any breach of this letter agreement by the Investor Group and any deemed breach of this letter agreement by any
of the Investor Group’s Representatives and by any other person to whom the Investor Group discloses any Confidential Information,
whether or not such disclosure is permitted hereunder, as if such Representatives or other persons were parties hereto and had
the Investor Group’s obligations hereunder.

 

    5

     

    

 

		9.	The Investor Group acknowledges and agrees that the Company would be irreparably injured by an
actual breach of this letter agreement and that monetary remedies would be inadequate to protect the Company against any actual
or threatened breach or continuation of any breach of this letter agreement. Without prejudice to any other rights and remedies
otherwise available to the Company under this letter agreement, the Company shall be entitled to equitable relief by way of injunction
or otherwise and specific performance of the provisions hereof upon satisfying the requirements to obtain such relief without the
necessity of posting a bond or other security, if the Investor Group or any of its Representatives breach or threaten to breach
any provision of this letter agreement. Such remedy shall not be deemed to be the exclusive remedy for a breach of this letter
agreement but shall be in addition to all other remedies available at law or equity to the non-breaching party.

 

		10.	The Investor Group agrees that (a) none of the Company or its Representatives shall have any
liability to the Investor Group or any of its Representatives resulting from the selection, use or content of the Confidential
Information by the Investor Group or its Representatives and (b) none of the Company or its Representatives makes any representation
or warranty, express or implied, as to the accuracy or completeness of any Confidential Information. This letter agreement shall
not create any obligation on the part of the Company or its Representatives to provide the Investor Group or its Representatives
with any Confidential Information, nor shall it entitle the Investor Group or its Representatives to participate in any meeting
of the Board or any committee thereof. All Confidential Information shall remain the property of the Company and its Affiliates.
Neither the Investor Group nor any of its Representatives shall by virtue of any disclosure of, and/or the Investor Group’s
or its Representatives’ use of, any Confidential Information acquire any rights with respect thereto; all such rights shall
remain exclusively with the Company and its Affiliates. The Investor Group and its Representatives shall not initiate contact with
any officer or employee of the Company concerning Confidential Information other than as permitted by the terms of the Settlement
Agreement, unless otherwise approved in writing by the Company; provided, however, the restrictions set forth in
this sentence shall not apply to the Investor Group Director, acting in his capacity as such, or any other officer or employee
of the Company who is also serving as a director.

 

		11.	Except as otherwise set forth herein, this letter agreement and the obligations and restrictions
hereunder shall terminate 18 months from the earlier of (a) the date on which the Investor Group Director ceases to be a director
of the Company and (b) the date on which the Investor Group delivers written notice to the Company that it no longer wishes to
receive any Confidential Information under this Agreement; provided however, that any liability for breach of this letter
agreement prior to termination under this Section 11 shall survive such termination.

 

		12.	No failure or delay by any party or any of its Representatives in exercising any right, power or
privilege under this letter agreement shall operate as a waiver thereof, and no modification hereof shall be effective, unless
in writing and signed by the Investor Group and the Company.

 

    6

     

    

 

		13.	The illegality, invalidity or unenforceability of any provision hereof under the laws of any jurisdiction
shall not affect its legality, validity or enforceability under the laws of any other jurisdiction, nor the legality, validity
or enforceability of any other provision hereof.

 

		14.	This letter agreement shall be governed by and construed in accordance with the laws of the State
of Delaware without giving effect to the choice of law principles of such state that may direct application of laws of another
jurisdiction. Each party hereto hereby irrevocably and unconditionally consents to the exclusive institution and resolution of
any action, suit or proceeding of any kind or nature with respect to or arising out of this letter agreement brought by any party
hereto in the United States District Court for the District of Delaware or, if there is no federal subject matter jurisdiction,
in the Delaware Court of Chancery. Each party hereto hereby irrevocably and unconditionally waives any objection to the laying
of venue of any action, suit or proceeding arising out of this letter agreement in such court, and further irrevocably and unconditionally
waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has
been brought in an inconvenient forum. The parties agree that a final judgment in any such dispute shall be conclusive and may
be enforced in other jurisdictions by suits on the judgment or in any other manner provided by law. EACH PARTY HERETO HEREBY IRREVOCABLY
WAIVES ANY AND ALL RIGHT TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF, OR RELATING TO, THIS LETTER AGREEMENT. In the
event of litigation relating to this letter agreement, if a court of competent jurisdiction determines that a party has breached
this letter agreement, then such breaching party shall be liable for, and shall pay, the reasonable legal fees, costs and expenses
that the non-breaching party has incurred in connection with such litigation, including any appeal therefrom. In addition, in the
event of litigation relating to this letter agreement or the Settlement Agreement between the Company and any member of the Investor
Group, if the Investor Group Director incurs any legal or other fees, costs or expenses in his or her capacity as a deponent, witness,
or other nonparty, the breaching party shall promptly, upon demand therefor, reimburse the Investor Group Director for all such
reasonable fees, costs and expenses.

 

		15.	Any notice or other communication required or permitted under this letter agreement to the Company
or the Investor Group shall be provided pursuant to Section 13 of the Settlement Agreement.

 

		16.	This letter agreement and the Settlement Agreement (including the exhibits thereto) constitute
the only agreement between the parties hereto with respect to the subject matter hereof and thereof and supersede all prior agreements,
understandings, negotiations and discussions, whether oral or written. For the avoidance of doubt, nothing in this letter agreement
supplements, modifies or amends the “Standstill Restrictions”, the entirety of which are contained in Section 3 of
the Settlement Agreement. This letter agreement may be amended only by an agreement in writing executed by the Company and the
Investor Group.

 

		17.	This letter agreement will be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns. Any assignment of this letter agreement by the Investor Group (including by operation of law)
or the Investor Group Director without the prior written consent of the Company shall be void ab initio. Any purchaser of
the Company or of all, or substantially all, the Company’s assets shall be entitled to the benefits of this letter agreement,
whether or not this letter agreement is assigned to such purchaser.

 

    7

     

    

 

		18.	Each party to this letter agreement acknowledges that it has been represented by counsel of its
choice throughout all negotiations that have preceded the execution of this letter agreement, and that it has executed this letter
agreement with the advice of such counsel. Each party and its counsel cooperated and participated in the drafting and preparation
of this letter agreement and the documents referred to herein, and any and all drafts relating thereto exchanged among the parties
hereto shall be deemed the work product of all of the parties and may not be construed against any party by reason of its drafting
or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this
letter agreement against any party that drafted or prepared it is of no application and is hereby expressly waived by each of the
parties hereto, and any controversy over interpretations of this letter agreement shall be decided without regards to events of
drafting or preparation.

 

		19.	This letter agreement may be executed in separate counterparts (including by fax, .jpeg, .gif,
..bmp and .pdf), each of which when so executed shall be an original, but all such counterparts shall together constitute one and
the same instrument.

 

[Signature Pages Follow]

 

    8

     

    

 

	 	Very truly yours,
	 	 
	 	KNOWLES CORPORATION
	 	 
	 	By:	 
	 	Name:	Jeffrey S. Niew
	 	Title:	President and Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURE PAGE TO CONFIDENTIALITY AGREEMENT

 

    

     

    

 

ACCEPTED AND AGREED TO BY:

	
        CALIGAN PARTNERS LP

         

         

        By: __________________________________

        Name:Samuel J. Merksamer

        Title:Partner

	 
	
        CALIGAN PARTNERS CV I LP

         

        By: Caligan Partners LP, its investment manager

         

         

        By:__________________________________

        Name:Samuel J. Merksamer

        Title: Partner

	 
	
        CALIGAN PARTNERS CV GP LLC

         

         

        By: __________________________________

        Name:Samuel J. Merksamer

        Title: Managing Member

	
         

        CALIGAN PARTNERS GP, LLC

         

         

        By: __________________________________

        Name:Samuel J. Merksamer

        Title: Managing Member

	 
	
        FALCON EDGE CAPITAL, LP

         

         

        By: __________________________________

        Name:Mark Cho

        Title:Authorized Signatory

	 
	
        FALCON EDGE (CAYMAN) GP, LTD.

         

         

        By: __________________________________

        Name:Mark Cho

        Title: Authorized Signatory

	 

 

SIGNATURE PAGE TO CONFIDENTIALITY AGREEMENT

    

     

    

 

	
        FALCON EDGE GLOBAL MASTER FUND, LP

         

        By: Falcon Edge Capital LP, its investment manager 

         

        By: __________________________________

        Name:Mark Cho

        Title: Authorized Signatory

	 
	
        MORAINE MASTER FUND, LP

         

        By: Falcon Edge Capital LP, its investment manager 

         

        By: __________________________________

        Name:Mark Cho

        Title: Authorized Signatory 

         

	
        PATRIOT GLOBAL MANAGEMENT, LP 

         

        By:__________________________________

        Name:Jonathan Christodoro

        Title: Authorized Signatory

	 
	
        SAMUEL J. MERKSAMER

         

        __________________________________

          

        DAVID E. JOHNSON

         

        __________________________________ 

	 
	
        JONATHAN CHRISTODORO

         

        __________________________________

        

         

	STEVEN F. MAYER

                                            

                                           __________________________________

  

 

 

SIGNATURE PAGE TO CONFIDENTIALITY AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]